
Company valuation, historical trends, and peer comparisons.
According to ALX Oncology Holdings Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 163.32M. This represents a change of 12.62% compared to the average of 145.01M of the last 4 quarters.
The mean historical Enterprise Value of ALX Oncology Holdings Inc. over the last ten years is 750.01M. The current 163.32M Enterprise Value has changed -78.22% with respect to the historical average. Over the past ten years (40 quarters), ALXO's Enterprise Value was at its highest in in the December 2020 quarter at 2.81B. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.
Average
750.01M
Median
569.09M
Minimum
49.48M
Maximum
3.00B
Discovering the peaks and valleys of ALX Oncology Holdings Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 358.11%
Maximum Annual Enterprise Value = 3.00B
Minimum Annual Increase = -86.37%
Minimum Annual Enterprise Value = 49.48M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 49.48M | -42.83% |
| 2024 | 86.54M | -86.37% |
| 2023 | 634.88M | 51.06% |
| 2022 | 420.29M | -16.49% |
| 2021 | 503.29M | -83.23% |
| 2020 | 3.00B | 358.11% |
| 2019 | 654.94M | 0.72% |
The current Enterprise Value of ALX Oncology Holdings Inc. (ALXO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
256.97M
5-year avg
338.90M
10-year avg
750.01M
ALX Oncology Holdings Inc.’s Enterprise Value is less than Annexon, Inc. (469.46M), greater than Bicycle Therapeutics plc (-203339324.00), less than Monte Rosa Therapeutics, Inc. (846.23M), less than Kymera Therapeutics, Inc. (10.39B), greater than Nkarta, Inc. (157.45M), less than Stoke Therapeutics, Inc. (1.57B), greater than Tenaya Therapeutics, Inc. (9.40M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 469.46M | $644.08M | |
| -203339324.00 | $253.72M | |
| 846.23M | $898.35M | |
| 10.39B | $10.69B | |
| 157.45M | $108.87M | |
| 1.57B | $1.67B | |
| 9.40M | $83.54M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ALX Oncology Holdings Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ALX Oncology Holdings Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is ALX Oncology Holdings Inc.'s Enterprise Value?
What is the highest Enterprise Value for ALX Oncology Holdings Inc. (ALXO)?
What is the 3-year average Enterprise Value for ALX Oncology Holdings Inc. (ALXO)?
What is the 5-year average Enterprise Value for ALX Oncology Holdings Inc. (ALXO)?
How does the current Enterprise Value for ALX Oncology Holdings Inc. (ALXO) compare to its historical average?